{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:09:34Z","timestamp":1790237374674,"version":"4.1.0"},"reference-count":47,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      alterations occur in a subset of biliary tract cancers (BTCs) and are often linked to disease progression and poor prognosis, yet targeted approaches remain underexplored.\n                      <jats:italic toggle=\"yes\">ERRFI1<\/jats:italic>\n                      , encoding the epidermal growth factor receptor (EGFR) inhibitor MIG6, is mutated in various cancers, including BTC, representing a potential predictive biomarker. We investigated whether loss of\n                      <jats:italic toggle=\"yes\">ERRFI1<\/jats:italic>\n                      function may enhance sensitivity to EGFR-targeted tyrosine kinase inhibitors (TKIs), presenting a potential therapeutic opportunity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      This is a retrospective multicenter study of patients with BTC harboring\n                      <jats:italic toggle=\"yes\">ERRFI1<\/jats:italic>\n                      alterations. Data were extracted from electronic health records following institutional approval.\n                      <jats:italic toggle=\"yes\">ERRFI1<\/jats:italic>\n                      alterations were classified based on the alteration type, variant allele frequencies were documented, and coalterations were analyzed. Treatment outcomes including response, time to progression (TTP), overall survival (OS), safety profiles, and tumor marker kinetics were noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Fourteen BTC patients with\n                      <jats:italic toggle=\"yes\">ERRFI1<\/jats:italic>\n                      mutations were identified in our database; the median age was 50 years, 64% were males; all cases were intrahepatic cholangiocarcinomas. Common coalterations included\n                      <jats:italic toggle=\"yes\">IDH1<\/jats:italic>\n                      (36%),\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      (29%), and\n                      <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                      (29%). All patients received gemcitabine-cisplatin as first-line treatment, and 79% received immune checkpoint inhibitors. Eight patients (57%) received EGFR TKIs. Best responses to EGFR therapy included three partial responses (2 responses lasting &gt;20 months), four stable diseases, and one progressive disease. The median TTP was 7 months (95% CI, 6 to 21 months). Treatment was well-tolerated: toxicities included rash (n = 2), transaminitis (n = 1), and diarrhea (n = 1). The median OS was 20 months (95% CI: 8-36 months); 50% remained alive at last follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">ERRFI1<\/jats:italic>\n                      mutations represent actionable biomarkers in BTC, with EGFR-targeted therapy demonstrating meaningful clinical benefit in this heavily pretreated population. These findings support integration of\n                      <jats:italic toggle=\"yes\">ERRFI1<\/jats:italic>\n                      testing into routine molecular profiling of BTC and other EGFR-driven malignancies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-00673","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:59:12Z","timestamp":1780516752000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-9474","authenticated-orcid":true,"given":"Supriya","family":"Peshin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Norton Community Hospital, Ballad Health, Norton, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-1789","authenticated-orcid":true,"given":"Fen","family":"Saj","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-7085","authenticated-orcid":true,"given":"Pashtoon M.","family":"Kasi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Therapeutics Research, City of Hope Orange County, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity","family":"David","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janio","family":"Szklaruk","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Kimana","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-480X","authenticated-orcid":true,"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunyoung S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-6647","authenticated-orcid":true,"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-2658","authenticated-orcid":true,"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-0941","authenticated-orcid":true,"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100378"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.007"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082039"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3375"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70301-1"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70212-8"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010543"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004135"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071574"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2021.07.002"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201744767"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200502013"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191593"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.342"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14447"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29350"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1142973"},{"key":"e_1_3_7_21_2","unstructured":"cbioportal: https:\/\/www.cbioportal.org\/"},{"key":"e_1_3_7_22_2","volume-title":"AACR Project GENIE: Powering Precision Medicine","author":"AACR","unstructured":"AACR: AACR Project GENIE: Powering Precision Medicine. https:\/\/www.aacr.org\/professionals\/research\/aacr-project-genie\/"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","unstructured":"Mody K Kasi PM Yang J et al: Circulating tumor DNA profiling of advanced biliary tract cancers. JCO Precis Oncol 10.1200\/PO.18.00324","DOI":"10.1200\/PO.18.00324"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2693"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1401"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3074"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05998"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2015.10.001"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0750"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa082"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0218"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000500"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3632"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.11.006"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3725"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216498"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-019-0091-4"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1305181"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35144-1"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112998"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1236246"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2014.11.009"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70073"},{"key":"e_1_3_7_44_2","first-page":"5785","article-title":"Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: Case report of disease progression on afatinib","volume":"15","author":"Kuznetsova O","year":"2023","unstructured":"Kuznetsova O, Lebedeva A, Kavun A, et al: Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: Case report of disease progression on afatinib. Am J Transl Res 15:5785-5790, 2023","journal-title":"Am J Transl Res"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173688"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.009"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02453"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1468"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:59:17Z","timestamp":1780516757000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/PO-25-00673"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00673","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500673"}}